JATT II Acquisition Corp

JATT II Acquisition Corp(JATT)资讯与事件

$12.000

-0.010 (-0.08%)收盘时

JATT 资讯

JATT 事件

8/21 10:00

Jatt II Acquisition Corp Trading Halted Due to Volatility

Jatt II Acquisition Corp trading halted, volatility trading pause

6/29 10:00

JATT II Acquisition Corp Ordinary Shares Trading Halted

JATT II Acquisition Corp Ordinary Shares trading halted, volatility trading pause

6/29 07:30

Talawar Tx and JATT II to Merge, Expected to Raise $285 Million

Talawar Tx and JATT II Acquisition Corp announced they have entered into a definitive business combination agreement. The combined company will operate as Talawar Therapeutics and is expected to trade on the Nasdaq Capital Market under the ticker symbol "TLWR". Available cash to the combined company at closing is anticipated to fund TALA-125 through a Phase 2b proof-of-concept study data readout in the second half of 2028. The business combination is expected to close in the second half of 2026, subject to customary closing conditions, including approval by JATT II shareholders and regulatory approvals. Upon closing, the combined company expects to receive $285 million (prior to the payment of transaction costs and assuming no redemptions by JATT II's public shareholders). Proceeds will be funded through a combination of $60 million held in a trust account by JATT II and a $225 million concurrent PIPE of common stock at $10.00 per share. The PIPE is led by founding investor Access Biotechnology and includes participation from Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, Farallon Capital Management, and other leading healthcare dedicated investors and mutual funds.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始